Dolby Laboratories, Inc.

Securities Trading Plans of Directors and Executive Officers

During the fiscal quarter ending March 27, 2026, the following directors and officers, as defined in Rule 16a-1(f), adopted a "Rule 10b5-1 trading arrangement" as defined in Regulation S-K Item 408, as follows:

On February 3, 2026, John Couling, our Senior Vice President, Entertainment, adopted a Rule 10b5-1 trading arrangement providing for the sale from time to time of an aggregate of up to 90,000 shares of our Class A common stock. The trading arrangement is intended to satisfy the affirmative defense in Rule 10b5-1(c). The duration of the trading arrangement is until February 3, 2027, or earlier if all transactions under the trading arrangement are completed.

On February 10, 2026, Robert Park, our Senior Vice President and Chief Financial Officer, amended his previously reported Rule 10b5-1 trading arrangement adopted August 26, 2025. The amended plan is intended to satisfy the affirmative defense in Rule 10b5-1(c) and provides that Mr. Park may sell up to 4,895 shares of Class A common stock. The duration of the amended trading arrangement is until February 10, 2027, or earlier if all transactions under the trading arrangement are completed.

On March 10, 2026, Kevin Yeaman, our Chief Executive Officer, President, and a member of our Board of Directors, terminated his previously reported Rule 10b5-1 trading arrangement adopted November 26, 2025.

No other directors or officers, as defined in Rule 16a-1(f), adopted and/orterminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement,” each as defined in Regulation S-K Item 408, during the fiscal quarter ending March 27, 2026.